Thermo Fisher Scientific Inc. (TMO) EBITDA Margin: 25.73%
Is Thermo Fisher Scientific Inc.’s EBITDA margin high or low?
Thermo Fisher Scientific Inc.'s EBITDA margin of 25.73% is in line with its 5-year average of 27.97%, near the low end of its 5-year range (25.73%–31.37%).
As of Tuesday, June 16, 2026. 3.36% below its 12-month average of 26.63%.
TMO EBITDA Margin Chart
TMO Average EBITDA Margin Chart
TMO Current vs Average EBITDA Margin Chart
TMO EBITDA Margin Metrics
EBITDA MARGIN
25.73%
EBITDA MARGIN AVG TTM
26.63%
EBITDA MARGIN AVG 3Y
26.49%
EBITDA MARGIN AVG 5Y
27.97%
EBITDA MARGIN AVG 10Y
26.55%
EBITDA MARGIN AVG 15Y
24.57%
EBITDA MARGIN AVG 20Y
22.81%
CURRENT VS TTM AVG
-3.36%
CURRENT VS 3Y AVG
-2.87%
CURRENT VS 5Y AVG
-8.03%
CURRENT VS 10Y AVG
-3.08%
CURRENT VS 15Y AVG
+4.70%
CURRENT VS 20Y AVG
+12.78%
TMO Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc. (TMO) | $177.08B | 25.73% | 26.63% | 26.49% | 27.97% |
| Amgen Inc. (AMGN)vs › | $189.27B | 45.99% | 42.98% | 46.17% | 46.55% |
| Novo Nordisk A/S (NVO)vs › | $193.53B | 50.71% | 50.83% | 48.60% | 47.92% |
| Gilead Sciences, Inc. (GILD)vs › | $157.69B | 46.12% | 30.77% | 33.17% | 31.82% |
| Abbott Laboratories (ABT)vs › | $156.41B | 26.06% | 25.95% | 26.39% | 26.63% |
| Pfizer Inc. (PFE)vs › | $148.76B | 24.12% | 26.30% | 27.39% | 29.84% |
| Intuitive Surgical, Inc. (ISRG)vs › | $148.26B | 39.63% | 38.59% | 35.51% | 35.18% |
| Danaher Corporation (DHR)vs › | $128.72B | 28.27% | 29.38% | 31.44% | 31.51% |
| CVS Health Corporation (CVS)vs › | $127.54B | 2.45% | 3.06% | 3.76% | 4.57% |
| Stryker Corporation (SYK)vs › | $119.06B | 25.14% | 23.50% | 23.36% | 22.67% |
Margin Comparison
Gross Margin
39.4%
EBITDA Margin
25.7%
Operating Margin
17.8%
Net Margin
15.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
Thermo Fisher Scientific Inc. EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Thermo Fisher Scientific Inc. EBITDA Margin FAQ
- What is the EBITDA margin for Thermo Fisher Scientific Inc. (TMO)?
- The EBITDA margin for TMO stock is 25.73%.
- Is Thermo Fisher Scientific Inc.'s EBITDA margin high or low?
- Thermo Fisher Scientific Inc.'s EBITDA margin of 25.73% is in line with its 5-year average of 27.97%, near the low end of its 5-year range (25.73%–31.37%).
- What is the TTM average EBITDA margin for Thermo Fisher Scientific Inc. (TMO)?
- The TTM average EBITDA margin for TMO stock is 26.63%.
- What is the 3Y average EBITDA margin for Thermo Fisher Scientific Inc. (TMO)?
- The 3Y average EBITDA margin for TMO stock is 26.49%.
- What is the 5Y average EBITDA margin for Thermo Fisher Scientific Inc. (TMO)?
- The 5Y average EBITDA margin for TMO stock is 27.97%.
- What is the 10Y average EBITDA margin for Thermo Fisher Scientific Inc. (TMO)?
- The 10Y average EBITDA margin for TMO stock is 26.55%.
- What is the 15Y average EBITDA margin for Thermo Fisher Scientific Inc. (TMO)?
- The 15Y average EBITDA margin for TMO stock is 24.57%.
- What is the 20Y average EBITDA margin for Thermo Fisher Scientific Inc. (TMO)?
- The 20Y average EBITDA margin for TMO stock is 22.81%.
Thermo Fisher Scientific Inc. EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | 25.73% |
| 2024-12-31 | 27.52% |
| 2023-12-31 | 26.12% |
| 2022-12-31 | 26.59% |
| 2021-12-31 | 30.52% |
| 2020-12-31 | 31.37% |
| 2019-12-31 | 27.50% |
| 2018-12-31 | 25.43% |
| 2017-12-31 | 24.16% |
| 2016-12-31 | 23.27% |
| 2015-12-31 | 23.81% |
| 2014-12-31 | 25.17% |
| 2013-12-31 | 19.72% |
| 2012-12-31 | 19.94% |
| 2011-12-31 | 18.63% |
| 2010-12-31 | 17.72% |
| 2009-12-31 | 18.13% |
| 2008-12-31 | 19.74% |
| 2007-12-31 | 18.24% |
| 2006-12-31 | 13.24% |
| 2005-12-31 | 16.55% |
| 2004-12-31 | 15.25% |
| 2003-12-31 | 13.32% |
| 2002-12-31 | 9.25% |
| 2001-12-31 | 12.13% |
| 2000-12-31 | 12.96% |
| 1999-12-31 | 14.66% |
| 1998-12-31 | 9.14% |
| 1997-12-31 | 10.44% |
| 1996-12-31 | 13.62% |
Related Metrics
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Marc N. Casper